Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM homeobox protein 3 (LHX3)
- Target
- LHX3
- Molecular classification
- Transcription factor, LIM homeobox protein family, LIM domain protein
01
Overview
LIM homeobox protein 3 (LHX3) is a member of the LIM homeobox transcription factor family characterized by the LIM domain, a cysteine-rich zinc-binding motif. LHX3 is essential for normal development of the pituitary gland and the specification of motor neurons. Its loss or mutation leads to syndromes such as combined pituitary hormone deficiency and rigid cervical spine. LHX3 acts by binding sequence-specific DNA motifs, positively regulating transcription of target genes, with co-factors including LDB1 and ISL1. While the broader LIM homeobox family has links to diverse diseases including cancer, direct involvement of LHX3 in oncogenesis is less well defined[1][2][3][4][5].
- Other names
- LIM/homeobox protein Lhx3LHX3HGNC:6595OMIM:600577UniProtKB:Q9UBR4LIM-3
02
Mechanism of action
Not applicable for drugs (no drugs known to target LIM homeobox 3 directly); general transcription factor modulation may apply if targeted indirectly.
03
Biological functions
Pituitary gland developmentMotor neuron specificationRegulation of specific gene transcription (including glycoprotein hormone alpha chain CGA and CHX10)Interneuron and motor neuron development (in cooperation with LDB1 and ISL1)
04
Disease associations
Combined pituitary hormone deficiencyHypothyroidism due to deficient transcription factors in pituitary development or functionRigid cervical spine syndromePotential roles in cancer through its family association (LIM homeobox genes, but direct evidence for LHX3 is limited)
05
Safety considerations
Direct therapeutic targeting of transcription factors such as LHX3 presents notable challenges, including potential off-target effectsrisk of disrupting essential developmental processesNo safety issues specific to drug targeting of LHX3 have been reported (as it is not a direct therapeutic target)
06
Biomarkers
Mutations in LHX3 gene can serve as genetic biomarkers for combined pituitary hormone deficiency
Beyond the preview
Go deeper on LIM homeobox protein 3 (LHX3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIM homeobox protein 3 (LHX3).